22:39Presales 0 + AI Strategy Makes Millions Buying POPCAT and MAGA, Now Buys PCHAIN for Another 12,000x Gains by January 202520:57Press Release 0 + BinaryX Announces Launch of Its AI Hero, Features Innovative PvP14:51security 0 + Binance partners with Japanese KYC provider despite privacy concerns18:00ethereum 0 + Undervalued ethereum competitor prompts shift in investor sentiment02:08Artificial Intelligence 0 + Crypto scams are going to ramp up with the rise of AI12:20Tech 0 + Booming AI demand spurs AI-based crypto growth amid the current US SEC onslaught
22:39Presales 0 + AI Strategy Makes Millions Buying POPCAT and MAGA, Now Buys PCHAIN for Another 12,000x Gains by January 2025
19:27 bull market 0 + Next phase of the bull run is ‘all about’ Bitcoin, not ETH or memecoins — Analyst23:42 0 + Binance’s exec exodus, Nasdaq to trade AI orders and SBF loses bail appeal: Hodler’s Digest, Sept. 3-912:09WorldCoin 0 + AI Tokens Record Lowest Weekly Volume Since January – A Sign Of Waning Interest?13:00Sponsored 0 + Advancements in AI to spark broader adoption of InQubeta and Bittensor 11:40#twitter 0 + Twitter suspends AI bot as Elon Musk dubs it crypto scam14:12Cryptocurrency 0 + AI-based Hasaki (HAHA) token pumps 694% after IDO
19:27 bull market 0 + Next phase of the bull run is ‘all about’ Bitcoin, not ETH or memecoins — Analyst
23:42 0 + Binance’s exec exodus, Nasdaq to trade AI orders and SBF loses bail appeal: Hodler’s Digest, Sept. 3-9
17:30Technology 0 + AI-based human gene editing breakthrough opens path to open-source cures to disease, slow aging19:40Technology 0 + Nasdaq receives SEC approval for AI-based trade orders20:06Polkadot 0 + InQubeta inspires Polkadot and other crypto projects to integrate AI11:15 0 + LayerAI (LAI) price prediction as AltSignals’ stage 1 presale nears end17:00Sponsored 0 + InQubeta is among 3 AI crypto projects investors can explore in 202301:41Sponsored 0 + Avorak AI trade algo continues to nail Solana price predictions this April
17:30Technology 0 + AI-based human gene editing breakthrough opens path to open-source cures to disease, slow aging
